Dr Jean-paul Castaigne

Biography

Prior to RYTVEL Biotech Dr Castaigne was President and CEO of Angiochem, a position he has held since September 2006. Angiochem leverages its platform technology to create drugs that cross the blood brain barrier to treat brain diseases. In this capacity, he has advanced multiple clinical and preclinical drug candidates and leads the company's financing and partnering activities. Prior to joining Angiochem, he was COO and CSO of Conjuchem Inc. (TSX: CJB), a Montreal-based biotech company. Prior to joining Conjuchem in 2000, he was Vice-President, worldwide Head of Global R&D at Group Fournier SA in France. Before that, he was with Novartis for over 10 years in a variety of international positions, including President and Managing Director for Sandoz Philippines and Director of Medical and R&D for Sandoz in France and as Corporate Vice-President, R&D, Medical and Regulatory in Canada, where he oversaw significant growth in the R&D operation.  Prior to RYTVEL Biotech Dr Castaigne was President and CEO of Angiochem, a position he has held since September 2006. Angiochem leverages its platform technology to create drugs that cross the blood brain barrier to treat brain diseases. In this capacity, he has advanced multiple clinical and preclinical drug candidates and leads the company's financing and partnering activities. Prior to joining Angiochem, he was COO and CSO of Conjuchem Inc. (TSX: CJB), a Montreal-based biotech company. Prior to joining Conjuchem in 2000, he was Vice-President, worldwide Head of Global R&D at Group Fournier SA in France. Before that, he was with Novartis for over 10 years in a variety of international positions, including President and Managing Director for Sandoz Philippines and Director of Medical and R&D for Sandoz in France and as Corporate Vice-President, R&D, Medical and Regulatory in Canada, where he oversaw significant growth in the R&D operation. 

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry